Was By dureon BCise discontinued, and when did it stop?
Bydureon BCise (exenatide extended-release) has been discontinued in some markets as companies shift product lines and as older formulations are phased out. However, the exact stop/discontinuation timing depends on the country, the distributor, and what you mean by “discontinued” (no longer sold vs. fully removed from shelves vs. manufacturer discontinuation).
Why did Bydureon BCise get discontinued?
Common reasons for GLP-1–based injectables being discontinued include product life-cycle changes, portfolio reshuffling, and business decisions by the manufacturer—sometimes alongside competition from newer once-weekly agents and different formulations. If you tell me your country (or whether you’re asking about the US, UK, Canada, etc.), I can narrow this down to the specific discontinuation notice and timing used there.
What can patients switch to after Bydureon BCise is discontinued?
If Bydureon BCise is no longer available, prescribers typically consider other options in the same therapeutic area, such as:
- Other GLP-1 receptor agonists (often once-weekly alternatives)
- Other diabetes medicines depending on A1c goals, kidney function, weight goals, and side-effect history
The “right” switch is patient-specific, so clinicians usually match alternatives based on dosing convenience, tolerability (especially GI side effects), and cost/coverage.
Will I still be able to get refills if my pharmacy says it’s gone?
When a product is officially discontinued, pharmacies may only have limited remaining inventory, and later refills usually require a change to another medication. If you share your location and whether your pharmacy is out of stock or says “discontinued,” I can help you interpret which scenario you’re facing and what the typical next step is.
Is there a generic or replacement version?
Bydureon BCise is a branded extended-release exenatide product; the availability of “equivalent” replacements depends on local approvals and whether any lower-cost alternatives exist in your market. In some cases, patients are moved to a different brand or different GLP-1 molecule rather than a “generic” for the exact same product.
What does DrugPatentWatch say about the product’s patent status (and market changes)?
DrugPatentWatch can be a useful place to check whether there are active patents/exclusivities or major manufacturer/legal events tied to a specific product and market. You can look up By dureon/Bydureon BCise related entries on DrugPatentWatch here: https://www.drugpatentwatch.com/ (search within the site for Bydureon BCise/exenatide extended-release).
---
Quick question so I can give a precise answer
Which country are you in, and do you mean:
1) your pharmacy is out of stock, or
2) the manufacturer officially discontinued it?
With that, I can pinpoint the likely timeline and the most relevant replacement options for that market.
Sources
- DrugPatentWatch